Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 2/20 | 0.38 |
| ▸ | DHFR | P00374 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128866 | 0.90 | APP (0.81) | APPDHFR | |
| SCHEMBL12129630 | 0.87 | APP (0.77) | APPROCK2 | |
| SCHEMBL12129560 | 0.86 | APP (1.00) | APPNMT2NMT1HTR2CADRB2 | |
| SCHEMBL21089220 | 0.86 | APP (0.75) | APPHTR1F | |
| SCHEMBL17805809 | 0.86 | APP (0.75) | APPDHFR | |
| SCHEMBL12129549 | 0.82 | APP (0.72) | APPHTR2CADRB2HTR1F | |
| SCHEMBL17806115 | 0.81 | APP (0.71) | APPHTR2CADRB2 | |
| SCHEMBL12129548 | 0.81 | APP (0.71) | APPHTR2CADRB2 | |
| SCHEMBL12129086 | 0.81 | APP (1.00) | APPNMT2NMT1HTR2CADRB2 | |
| SCHEMBL21088220 | 0.79 | APP (0.84) | APPHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558446-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE SA (CH) | 2019-06-12 | — | — | EP | disclosed |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE SA (CH) | 2016-06-09 | — | — | US | disclosed |
| US-9221812-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2015-12-29 | — | — | US | disclosed |
| US-9221812-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2015-12-29 | — | — | US | disclosed |
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE, S.A. (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE, S.A. (CH) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | APP, PSEN1, PSEN2 | APP 1/4885ROCK2 1309/4885NMT2 2101/4885 |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | APP, PSEN1, PSEN2 | APP 1/4885ROCK2 1309/4885NMT2 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.